Advertisement

Topics

Study to Evaluate Imatinib in Desmoid Tumors

2015-06-01 23:28:42 | BioPortfolio

Published on BioPortfolio: 2015-06-01T23:28:42-0400

Clinical Trials [405 Associated Clinical Trials listed on BioPortfolio]

A Trial of Imatinib for Patients With Aggressive Desmoid Tumor (Aggressive Fibromatosis)

Aggressive fibromatosis (AF, also known as desmoid tumor) is a fibroproliferative neoplasm that typically arises in the abdomen but can develop at other anatomic sites, most commonly in th...

Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis

RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I/II trial is studying the side effects of imat...

National Clinical-biological Prospective Cohort of Incident Cases of Aggressive Fibromatosis (ALTITUDES)

The purpose of this study is to constitute the French largest Aggressive fibromatosis cohort.

Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis

This randomized phase III trial compares the effects, good and/or bad, of sorafenib tosylate in treating patients with desmoid tumors or aggressive fibromatosis. Sorafenib tosylate may sto...

BioHFS - Biomarker for Hyaline Fibromatosis Syndrome

Development of a new MS-based biomarker for the early and sensitive diagnosis of Hyaline fibromatosis syndrome from plasma

PubMed Articles [1135 Associated PubMed Articles listed on BioPortfolio]

Systemic therapy of aggressive fibromatosis in children and adolescents: Report of the Cooperative Weichteilsarkom Studiengruppe (CWS).

Treatment algorithms for patients with aggressive fibromatosis (AF) are challenging. There are limited data available about the use of systemic therapy (ST) in pediatric patients with AF.

Multivisceral Transplant is a Viable Treatment Option for Patients with Nonresectable Intraabdominal Fibromatosis.

Intraabdominal fibromatosis often involves the mesentery root which is nonresectable by conventional surgery. Multivisceral transplant (MVT), as a potential cure to nonresectable fibromatosis, has rar...

Can therapeutic drug monitoring increase the safety of Imatinib in GIST patients?

Imatinib at 400 mg daily is the standard treatment for patients affected with CML and GIST. The intervariability in plasma concentration is very significant. In many reports, a good therapeutic effec...

Primary imatinib failure rescued by dasatinib and maintained by reintroduction of imatinib.

An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG).

Desmoid-type fibromatosis is a rare and locally aggressive monoclonal, fibroblastic proliferation characterized by a variable and often unpredictable clinical course. Currently, there is no establishe...

Medical and Biotech [MESH] Definitions

A childhood counterpart of abdominal or extra-abdominal desmoid tumors, characterized by firm subcutaneous nodules that grow rapidly in any part of the body but do not metastasize. The adult form of abdominal fibromatosis is FIBROMATOSIS, ABDOMINAL. (Stedman, 25th ed)

A fibromatosis of the plantar fascia characterized by thickening of the fibrous bands on the plantar aponeurosis in the sole of the foot and toes.

A pyrimidine and thiazole derived ANTINEOPLASTIC AGENT and PROTEIN KINASE INHIBITOR of BCR-ABL KINASE. It is used in the treatment of patients with CHRONIC MYELOID LEUKEMIA who are resistant or intolerant to IMATINIB.

A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors.

A fibromatosis of the palmar fascia characterized by thickening and contracture of the fibrous bands on the palmar surfaces of the hand and fingers. It arises most commonly in men between the ages of 30 and 50.

More From BioPortfolio on "Study to Evaluate Imatinib in Desmoid Tumors"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial